Abstract
Nelfinavir (Viracept®) was originally designed as a specific HIV protease inhibitor and, since its introduction in 1997, has served as an effective, reliable, and well-tolerated HIV drug. Although nelfinavir is being increasingly displaced by second generation HIV protease inhibitors that allow better combination treatments, it has again become a focus of interest due to an interesting paradoxical effect: nelfinavir inhibits experimentally-induced tissue degeneration or cell damage by preventing loss of the mitochondrial membrane potential, and even protects mitochondria in cancer cells but, conversely, it selectively induces a mitochondria-independent cell death mechanism in cancer cells by the so-called endoplasmic reticulum/unfolded protein stress response, allowing nelfinavir to act on otherwise chemo-resistant cancer cells. Furthermore, anti-microbial effects of nelfinavir have been described, including an efficacy against malaria, tuberculosis, and SARS, mostly by cross-reacting with microbial aspartic proteases. Several cancer-related clinical studies on nelfinavir as a single agent or in combination therapies have been launched and are expected to add to the usefulness of this versatile drug for cancer treatment strategies or other purposes.
Keywords: Nelfinavir, HIV, protease inhibitor, cancer, endoplasmic reticulum, apoptosis, mitochondria
Current Molecular Pharmacology
Title: New Prospects for Nelfinavir in Non-HIV-Related Diseases
Volume: 3
Author(s): Ansgar Bruning, Andrea Gingelmaier, Klaus Friese and Ioannis Mylonas
Affiliation:
Keywords: Nelfinavir, HIV, protease inhibitor, cancer, endoplasmic reticulum, apoptosis, mitochondria
Abstract: Nelfinavir (Viracept®) was originally designed as a specific HIV protease inhibitor and, since its introduction in 1997, has served as an effective, reliable, and well-tolerated HIV drug. Although nelfinavir is being increasingly displaced by second generation HIV protease inhibitors that allow better combination treatments, it has again become a focus of interest due to an interesting paradoxical effect: nelfinavir inhibits experimentally-induced tissue degeneration or cell damage by preventing loss of the mitochondrial membrane potential, and even protects mitochondria in cancer cells but, conversely, it selectively induces a mitochondria-independent cell death mechanism in cancer cells by the so-called endoplasmic reticulum/unfolded protein stress response, allowing nelfinavir to act on otherwise chemo-resistant cancer cells. Furthermore, anti-microbial effects of nelfinavir have been described, including an efficacy against malaria, tuberculosis, and SARS, mostly by cross-reacting with microbial aspartic proteases. Several cancer-related clinical studies on nelfinavir as a single agent or in combination therapies have been launched and are expected to add to the usefulness of this versatile drug for cancer treatment strategies or other purposes.
Export Options
About this article
Cite this article as:
Bruning Ansgar, Gingelmaier Andrea, Friese Klaus and Mylonas Ioannis, New Prospects for Nelfinavir in Non-HIV-Related Diseases, Current Molecular Pharmacology 2010; 3 (2) . https://dx.doi.org/10.2174/1874467211003020091
DOI https://dx.doi.org/10.2174/1874467211003020091 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Disparity in Pediatric Diseases
Current Molecular Medicine Inhibition of Bacterial Carbonic Anhydrases as a Novel Approach to Escape Drug Resistance
Current Topics in Medicinal Chemistry Differential Expression of Resistant and Efflux Pump Genes in MDR-TB Isolates
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Treatment of Psoriasis with Biologics
Current Drug Discovery Technologies Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs
Current Pharmaceutical Design Xenicane Natural Products: Biological Activity and Total Synthesis
Current Pharmaceutical Design Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic: Computer-Aided Drug Design, Synthesis and Evaluation of New Anti-Cancer Drugs)
Current Topics in Medicinal Chemistry Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Synthesis of Novel Quinolone and Coumarin Based 1,3,4-Thiadiazolyl and 1,3,4-Oxadiazolyl N-Mannich Bases as Potential Antimicrobials
Letters in Organic Chemistry Pyrrole: Chemical Synthesis, Microwave Assisted Synthesis, Reactions and Applications: A Review
Current Organic Chemistry Mitochondrial and Plastid Functions as Antimalarial Drug Targets
Current Drug Targets - Infectious Disorders HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Infectious Disorders - Drug Targets A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Pharmacophore and Docking Based Virtual Screening of Validated Mycobacterium tuberculosis Targets
Combinatorial Chemistry & High Throughput Screening Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies